Aldosterone Synthase Inhibitors: Emerging Therapeutic Strategies in Resistant Hypertension. (PubMed, Life (Basel)) - Sep 27, 2026 - "Recent clinical trials of baxdrostat, lorundrostat, vicadrostat, and dexfadrostat have demonstrated clinically meaningful reductions in blood pressure and albuminuria with acceptable safety profiles. Based on the positive trial data, baxdrostat has become the first in class ASI to be approved by regulatory authorities for management of uncontrolled hypertension."
Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Hypertension • Nephrology • Renal Disease • CYP11B1
|
|
Abhishek Singh; Akash Batta; Akshyaya Pradhan; Kunal Mahajan; Marco Alfonso Perrone; Monika Bhandari; Pravesh Vishwakarma
|